SCHEMBL4702918

SCHEMBL4702918

CCOC(=O)c1cc(-c2ccc(OCCc3cnc4c(c3)C(=O)N(C)c3cccnc3N4CC)c(C)c2)no1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.68
CYP2C9 P11712 3/20 0.68
CYP2C19 P33261 3/20 0.68
CYP1A2 P05177 1/20 0.53
BRD4 O60885 2/20 0.32
TDP2 O95551 2/20 0.31
ABL1 P00519 1/20 0.31
RIN1 Q13671 1/20 0.31
PABPC1 P11940 1/20 0.31
APOBEC3A P31941 1/20 0.31
EIF4H Q15056 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
GABRA1 P14867 2/20 0.31
GABRG2 P18507 2/20 0.31
GABRB3 P28472 2/20 0.31
GABRA5 P31644 2/20 0.31
GABRA3 P34903 2/20 0.31
GABRA2 P47869 2/20 0.31
GABRB2 P47870 1/20 0.31
GABRA6 Q16445 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4705706 0.93 CYP3A4 (0.74) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL4704413 0.84 CYP3A4 (0.69) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL4704222 0.84 CYP3A4 (0.71) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL4704791 0.84 CYP2C9 (0.71) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL4700952 0.83 CYP3A4 (0.73) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL4704900 0.83 CYP3A4 (0.85) CYP3A4CYP2C9CYP2C19CYP1A2
SCHEMBL4703039 0.83 CYP2C9 (0.74) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL13964181 0.82 CYP3A4 (0.79) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL4702288 0.82 CYP3A4 (0.71) CYP3A4CYP2C9CYP2C19CYP1A2BRD4
SCHEMBL4705688 0.82 CYP3A4 (0.75) CYP3A4CYP2C9CYP2C19CYP1A2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506195-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2008-10-29 EP disclosed
US-6806265-B2 FOR THERAPY AND PROPHYLAXIS OF HIV INFECTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-10-19 US disclosed
US-20040006071-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006071-A1 Non-nucleoside reverse transcriptase inhibitors CBR1, POLR2H, SUB1 CYP3A4 257/4885CYP2C9 778/4885CYP2C19 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.